Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001140361-22-028197
Filing Date
2022-08-04
Accepted
2022-08-04 16:10:27
Documents
12

Document Format Files

Seq Description Document Type Size
1 424B3 ny20004078x20_424b3.htm 424B3 6660386
2 logo_centerviewpartnersv2.jpg GRAPHIC 20936
3 logo_eq.jpg GRAPHIC 19579
4 logo_georgeson2.jpg GRAPHIC 27678
5 ny20004078x20_flowchart01.jpg GRAPHIC 74519
6 ny20004078x20_flowchart02.jpg GRAPHIC 119546
7 ny20004078x20_flowchart03.jpg GRAPHIC 128125
8 ny20004078x20_flowchartx1.jpg GRAPHIC 64922
9 ny20004078x20_flowchartx2.jpg GRAPHIC 104888
10 ny20004078x20_flowchartx3.jpg GRAPHIC 108201
11 ny20004078x20_piechart01.jpg GRAPHIC 62309
12 ny20004078x20_piechart02.jpg GRAPHIC 47804
  Complete submission text file 0001140361-22-028197.txt   7731585
Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 424B3 | Act: 33 | File No.: 333-263667 | Film No.: 221136635
SIC: 2835 In Vitro & In Vivo Diagnostic Substances